Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7580 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7580-7580 ◽

Cited By ~ 1

Author(s):

R. Govindan ◽

C. Zergebel ◽

K. Saito ◽

J. H. Schiller

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non–Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.06.010 ◽

2015 ◽

Vol 16 (1) ◽

pp. 57-59 ◽

Cited By ~ 11

Author(s):

Morena Fasano ◽

Carminia Maria Della Corte ◽

Annalisa Capuano ◽

Ferdinando Carlo Sasso ◽

Federica Papaccio ◽

...

Keyword(s):

Phase Ii Study ◽

Stage Iv ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Lung Cancer Patients ◽

Line Therapy ◽

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

ESMO Open ◽

10.1136/esmoopen-2016-000132 ◽

2017 ◽

Vol 2 (2) ◽

pp. e000132 ◽

Cited By ~ 20

Author(s):

Floriana Morgillo ◽

Morena Fasano ◽

Carminia Maria Della Corte ◽

Ferdinando Carlo Sasso ◽

Federica Papaccio ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Advanced Lung Cancer ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

1320TiP The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1959 ◽

2021 ◽

Vol 32 ◽

pp. S1030

Author(s):

J. Sun ◽

L. Xie ◽

Y. Feng ◽

S. Qin

Keyword(s):

Lung Cancer ◽

Stereotactic Body Radiation Therapy ◽

Phase Ii Study ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Open Label ◽

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.02.009 ◽

2021 ◽

Author(s):

Fiona Blackhall ◽

Kevin Jao ◽

Laurent Greillier ◽

Byoung Chul Cho ◽

Konstantin Penkov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

Phase 3 ◽

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.01.008 ◽

2019 ◽

Vol 14 (5) ◽

pp. 903-913 ◽

Cited By ~ 38

Author(s):

Jean-Louis Pujol ◽

Laurent Greillier ◽

Clarisse Audigier-Valette ◽

Denis Moro-Sibilot ◽

Lionel Uwer ◽

...

Keyword(s):

Lung Cancer ◽

Cell Death ◽

Programmed Cell Death ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)

Tumor Biology ◽

10.1007/s13277-016-5031-0 ◽

2016 ◽

Vol 37 (8) ◽

pp. 11479-11484 ◽

Cited By ~ 2

Author(s):

Rencui Quan ◽

Jiaxing Huang ◽

Nan Chen ◽

Wenfeng Fang ◽

Zhihuang Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Retrospective Analysis ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

9121 POSTER A Multi-center, Open, Randomized, Phase II Study to Investigate the Sequential Administration of Docetaxel and Intermittent Erlotinib Versus Erlotinib as a Second-line Therapy for Advanced Non-small Cell Lung Cancer (NSCLC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)72433-9 ◽

2011 ◽

Vol 47 ◽

pp. S630

Author(s):

F. Aparisi ◽

A. Sánchez ◽

V. Giner ◽

J. Mufioz ◽

G. Esquerdo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Sequential Administration

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7035 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7035-7035 ◽

Cited By ~ 7

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19107 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19107-e19107

Author(s):

Devika Das ◽

Francisco Robert ◽

Rodolfo Bordoni ◽

Stefan C. Grant ◽

Mansoor N. Saleh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽